FG-8205

FG-8205 is a pharmaceutical drug currently under development for the treatment of various neurodegenerative diseases. It is a small molecule drug that has shown promise in preclinical studies for its potential to slow the progression of diseases such as Parkinson's disease and Alzheimer's disease.

Mechanism of Action

FG-8205 works by targeting the mitochondria, the energy-producing structures within cells. In neurodegenerative diseases, the mitochondria often become damaged and dysfunctional, leading to cell death. FG-8205 is designed to protect the mitochondria and enhance their function, thereby preserving the health and viability of neurons.

Development and Clinical Trials

The development of FG-8205 is being led by Fountain Therapeutics, a biopharmaceutical company specializing in the development of therapies for age-related diseases. The drug is currently in the early stages of clinical trials, with results expected in the coming years.

Potential Applications

While FG-8205 is primarily being developed for the treatment of Parkinson's and Alzheimer's, its mechanism of action suggests that it could potentially be used in the treatment of other neurodegenerative diseases as well. These include Huntington's disease, ALS, and various forms of dementia.

See Also

• Neurodegenerative diseases
• Mitochondrial dysfunction
• Parkinson's disease
• Alzheimer's disease

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!

FG-8205

• 
  FG-8205